Clinical trials: Patients With Type 2 Diabetes
Type 2 Diabetes
To Evaluate Safety and Tolerability After Multiple Oral Doses of AZD1656 in Type 2 Diabetes Patients on Top of Insulin
The purpose of this study is to assess safety and tolerability of AZD1656 after multiple repeated oral doses in patients with type 2 diabetes on top of insulin.
- Trial name
- NCT00768105
- Testing
- AZD1656
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- AstraZeneca
Diabetes Mellitus, Type 2
A Study Based on Data From German Sick Funds That Looks at the Costs of Treatment of Type-2 Diabetic Patients With Empagliflozin vs. DPP-4 Inhibitors vs. GLP-1 Receptor Agonists
Empagliflozin vs. Dipeptidyl Peptidase 4 (DPP-4) Inhibitors and Glucagon-like Peptide-1 Receptor Agonists (GLP-1-RA) Cost of Care Study: a German claims data analysis
- Trial name
- NCT04295005
- Testing
- Empagliflozin, DPP-4i, GLP-1-RA
- Where
- Germany
- Volunteers
- 24,500 people
- Sponsor
- Boehringer Ingelheim
Coronary Arteriosclerosis, Diabetes Mellitus, Type 2
Establish The Benefits Of Using Various Starting Doses Of Atorvastatin On Achievement Of Cholesterol Targets (ACTFAST)
Physicians tend to always use the lowest dose of statins to initiate therapy even in subjects who require large reductions in cholesterol.
- Conditions
- Coronary Arteriosclerosis, Diabetes Mellitus, Type 2, Cerebrovascular Accident, Dyslipidemia
- Trial name
- ACTFAST (NCT00442845)
- Testing
- Atorvastatin (Lipitor)
- Where
- 121 sites in Cameroon, Canada and 3 more
- Volunteers
- 2,080 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Diabetes, Diabetes Mellitus, Type 2
Comparison of Insulin Detemir With Insulin Glargine in Type 2 Diabetes
This trial is conducted in the United States of America (USA). The purpose of this study is to determine if the use of insulin detemir in combination with insulin aspart is safe and at least as effective as insulin glargine in…
- Trial name
- NCT00106366
- Testing
- insulin detemir, insulin glargine, insulin aspart
- Where
- 78 sites in United States, Canada and 1 more
- Volunteers
- 389 people
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus, Type 2
Empagliflozin (BI 10773) in Type Two Diabetes (T2D) Patients, Open Label Extension
The objective of the current study is to investigate the safety and efficacy of BI 10773 in 2 different doses compared to Metformin or to Sitagliptin given for 78 weeks in different modalities of treatment in patients with type 2…
- Trial name
- NCT00881530
- Testing
- BI 10773, Metformin, Sitagliptin
- Where
- 137 sites in United States, Austria and 19 more
- Volunteers
- 660 people
- Sponsor
- Boehringer Ingelheim
Chronic Kidney Disease, Type 2 Diabetes
A Study of RTA 402 in Chronic Kidney Disease (CKD) Patients With Type 2 Diabetes Mellitus
A Phase 2 study of RTA 402 in Chronic kidney disease (CKD) patients with type 2 diabetes mellitus.
- Trial name
- NCT01574365
- Testing
- RTA 402
- Where
- Japan
- Volunteers
- 53 people
- Sponsor
- Kyowa Kirin Co., Ltd.
Diabetes Mellitus
Safety Study of TAK-559 in Treating Subjects With Type 2 Diabetes Mellitus
The purpose of this study was to determine the long-term safety of TAK-559, once daily (QD), in subjects with Type 2 Diabetes.
- Trial name
- NCT00762112
- Testing
- TAK-559
- Volunteers
- 316 people
- Sponsor
- Takeda
Obesity and Type 2 Diabetes
BMS-646256 in Obese and Overweight Type 2 Diabetics
This is a placebo-controlled, randomized, double-blind, parallel arm, multicenter, dose-ranging phase IIb trial to assess glycemic and weight loss efficacy and safety of BMS-646256 in overweight and obese patients with type 2…
- Trial name
- NCT00541567
- Testing
- ibipinabant
- Volunteers
- 600 people
- Sponsor
- Solvay Pharmaceuticals
Type 2 Diabetes
GALLANT 2 Tesaglitazar vs. Placebo
This is a 24-week randomized, double-blind, parallel-group, multi-center, placebo-controlled study of tesaglitazar (0.5 and 1 mg) in patients with type 2 diabetes, not adequately controlled on diet and lifestyle advice alone…
- Trial name
- NCT00252772
- Testing
- Tesaglitazar, Dietary and Lifestyle counseling
- Where
- 14 sites in Finland
- Volunteers
- 80 people
- Sponsor
- AstraZeneca
Type 2 Diabetes Mellitus
Safety and Efficacy of LX4211 With Metformin in Type 2 Diabetes Patients With Inadequate Glycemic Control on Metformin
This study is intended to assess the effect on HbA1c of different dose regimens of LX4211 in combination with metformin in subjects with Type 2 Diabetes Mellitus who have inadequate glycemic control on metformin monotherapy.
- Trial name
- NCT01376557
- Testing
- 75 mg LX4211, 200 mg LX4211, 400 mg LX4211
- Where
- 56 sites in United States
- Volunteers
- 299 people
- Sponsor
- Lexicon Pharmaceuticals
Diabetes Mellitus, Type 2
A Study of LY3209590 in Japanese Participants With Type 2 Diabetes Mellitus
The main purpose of this study is to evaluate the safety of a study drug known as LY3209590 in Japanese participants with type 2 diabetes. Side effects and tolerability will be documented.
- Trial name
- NCT04276428
- Testing
- LY3209590, Insulin Degludec
- Where
- 3 sites in Japan
- Volunteers
- 28 people
- Sponsor
- Eli Lilly and Company
Type 2 Diabetes
Study to Assess the Efficacy and Safety of Liraglutide in the Treatment of Type 2 Diabetes
Liraglutide injection is a glucagon-like peptide-1 (GLP-1) analogue that activates the cyclic adenosine monophosphate (cAMP) and mitogen-activated protein kinase (MAPK) pathway by binding to the GLP-1 receptor (GLP-1R),thus,it…
- Trial name
- NCT04373967
- Testing
- Victoza®., Metformin Hydrochloride, TQZ2451
- Where
- 46 sites in China
- Volunteers
- 424 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Healthy, Type 2 Diabetes Mellitus
A Study of LY3537021 in Healthy Participants and Participants With Type 2 Diabetes Mellitus
The main purpose of this study is to learn more about the safety of LY3537021 and any side effects that might be associated with it in healthy participants and participants with type 2 diabetes mellitus (T2DM).
- Trial name
- NCT04586907
- Testing
- LY3537021
- Where
- Singapore
- Volunteers
- 85 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Type-II Diabetes
Postbiotic MBS and Metformin Combination in Patients With T2DM
The primary objective is to evaluate the effect of MBS treatment in human subjects, and to validate its impact on intestinal flora and diabetes symptoms on diabetic patients undertaking metformin.
- Trial name
- NCT04639492
- Testing
- MBS oral solution
- Where
- Taiwan
- Volunteers
- 14 people
- Sponsor
- Microbio Co Ltd
Diabetes Mellitus, Type 2
Remote Study Collecting Blood Glucose Values and Activity Data in Patients With Type 2 Diabetes on Different Treatments
Earlier protocol ID was NN1250-4630, protocol ID is changed to NN1535-7774. The purpose of this study is to collect blood glucose values and activity data in patients with type 2 diabetes for approximately 12 weeks using…
- Trial name
- NCT04809311
- Testing
- Oral antidiabetetic drugs, Basal insulin, Glucagon-like peptide-1 (GLP-1)
- Where
- Denmark
- Volunteers
- 156 people
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus Type 2
Safety, Pharmacokinetics (PK) and Pharmacodynamics (PD) of Multiple Oral Bedtime Doses of ORMD-0801 in Adult Patients With Type 2 Diabetes Mellitus (T2DM)
The purpose of this study is to test the safety and pharmacodynamics of an oral formulation of insulin in subjects with Type 2 Diabetes.
- Trial name
- NCT01889667
- Testing
- ORMD-0801 Dose # 1, ORMD-0801 Dose # 2
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Oramed, Ltd.
Overweight or Obesity, Type 2 Diabetes
Phase 1 to Study Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of NA-931 in Obese Participants and Patients With Type 2 Diabetes Mellitus
A randomized, double-blind, placebo-controlled, dose escalation, first in human study designed to assess the safety and tolerability, pharmacokinetics, and pharmacodynamics of NA-931 when administered as single and…
- Trial name
- T2DM (NCT06615700)
- Testing
- NA-931
- Where
- 2 sites in Australia
- Volunteers
- 74 people, healthy volunteers welcome
- Sponsor
- Biomed Industries, Inc.
Chronic Kidney Disease, Type 2 Diabetes Mellitus
A Study Using Surveys to Learn More About Treatment With Steroidal Mineralocorticoid Receptor Antagonists, How They Are Used, What Side Effects They Have, and How Satisfied People Who Receive Them Are in the US
This is an observational study in which patients with chronic kidney diseases (CKD), type 2 diabetes (T2D) or heart failure (HF) who are current or past users of sMRA therapies are studied.
- Conditions
- Chronic Kidney Disease, Type 2 Diabetes Mellitus, Heart Failure
- Trial name
- NCT05407662
- Testing
- sMRA therapies
- Where
- United States
- Volunteers
- 600 people
- Sponsor
- Bayer
Diabetes Mellitus, Type 2
A Phase 1 Study to Evaluate the Effect of GSK256073, an HM74A Receptor Agonist, on Glucose and NEFA Levels in Type 2 Diabetics
The aim of this study is to verify whether a significant decrease in glucose levels can be achieved with the HM74A agonist GSK256073 in type 2 diabetic patients.
- Trial name
- NCT01147861
- Testing
- GSK256073
- Where
- 4 sites in United States
- Volunteers
- 39 people
- Sponsor
- GlaxoSmithKline
Diabetes Mellitus, Type 2
The Effects of LY2409021 on the Liver
This is a study that involves multiple doses of study drug (60 mg of LY2409021, 15 mg of LY2409021 or placebo) taken as capsules by mouth on a daily basis for 28 days.
- Trial name
- NCT01588366
- Testing
- LY2409021
- Where
- Singapore
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.